Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients - A pilot study

Akber Saifullah, Bruce A. Watkins, Chandan Saha, Yong Li, Sharon Moe, Allon Friedman

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background. We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers. Methods. Twenty-seven subjects were randomized in a 2:1 ratio to either 1.3 g of EPA + DHA daily or placebo. Results. At baseline, 83% of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean ± SD,% weight) - EPA: 0.3 ± 0.2, DHA: 2.9 ± 2.0, and ratio of n-6/n-3 PUFA: 4.2 ± 1.3. Supplementation induced large increases in mean blood EPA and DHA levels (% increase, P-value vs placebo group): erythrocyte - EPA: +400%, P = 0.0018, DHA: +205%, P < 0.0001; plasma - EPA: +275%, P = 0.0003, DHA: +69%, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 ± 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 ± 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted. Conclusions. Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit.

Original languageEnglish
Pages (from-to)3561-3567
Number of pages7
JournalNephrology Dialysis Transplantation
Volume22
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Fish Oils
Omega-3 Fatty Acids
C-Reactive Protein
Renal Dialysis
Placebos
Erythrocytes
Biomarkers
American Heart Association
Eicosapentaenoic Acid
Docosahexaenoic Acids
Unsaturated Fatty Acids
Fishes
Triglycerides
Cardiovascular Diseases
Clinical Trials
Weights and Measures

Keywords

  • C-reactive protein
  • Fish oil
  • Haemodialysis
  • n-3
  • Omega-3
  • Triglyceride

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients - A pilot study. / Saifullah, Akber; Watkins, Bruce A.; Saha, Chandan; Li, Yong; Moe, Sharon; Friedman, Allon.

In: Nephrology Dialysis Transplantation, Vol. 22, No. 12, 12.2007, p. 3561-3567.

Research output: Contribution to journalArticle

@article{ad2783c888bd4f9f9eac4f9a7b54cceb,
title = "Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients - A pilot study",
abstract = "Background. We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers. Methods. Twenty-seven subjects were randomized in a 2:1 ratio to either 1.3 g of EPA + DHA daily or placebo. Results. At baseline, 83{\%} of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean ± SD,{\%} weight) - EPA: 0.3 ± 0.2, DHA: 2.9 ± 2.0, and ratio of n-6/n-3 PUFA: 4.2 ± 1.3. Supplementation induced large increases in mean blood EPA and DHA levels ({\%} increase, P-value vs placebo group): erythrocyte - EPA: +400{\%}, P = 0.0018, DHA: +205{\%}, P < 0.0001; plasma - EPA: +275{\%}, P = 0.0003, DHA: +69{\%}, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 ± 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 ± 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted. Conclusions. Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit.",
keywords = "C-reactive protein, Fish oil, Haemodialysis, n-3, Omega-3, Triglyceride",
author = "Akber Saifullah and Watkins, {Bruce A.} and Chandan Saha and Yong Li and Sharon Moe and Allon Friedman",
year = "2007",
month = "12",
doi = "10.1093/ndt/gfm422",
language = "English",
volume = "22",
pages = "3561--3567",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients - A pilot study

AU - Saifullah, Akber

AU - Watkins, Bruce A.

AU - Saha, Chandan

AU - Li, Yong

AU - Moe, Sharon

AU - Friedman, Allon

PY - 2007/12

Y1 - 2007/12

N2 - Background. We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers. Methods. Twenty-seven subjects were randomized in a 2:1 ratio to either 1.3 g of EPA + DHA daily or placebo. Results. At baseline, 83% of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean ± SD,% weight) - EPA: 0.3 ± 0.2, DHA: 2.9 ± 2.0, and ratio of n-6/n-3 PUFA: 4.2 ± 1.3. Supplementation induced large increases in mean blood EPA and DHA levels (% increase, P-value vs placebo group): erythrocyte - EPA: +400%, P = 0.0018, DHA: +205%, P < 0.0001; plasma - EPA: +275%, P = 0.0003, DHA: +69%, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 ± 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 ± 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted. Conclusions. Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit.

AB - Background. We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers. Methods. Twenty-seven subjects were randomized in a 2:1 ratio to either 1.3 g of EPA + DHA daily or placebo. Results. At baseline, 83% of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean ± SD,% weight) - EPA: 0.3 ± 0.2, DHA: 2.9 ± 2.0, and ratio of n-6/n-3 PUFA: 4.2 ± 1.3. Supplementation induced large increases in mean blood EPA and DHA levels (% increase, P-value vs placebo group): erythrocyte - EPA: +400%, P = 0.0018, DHA: +205%, P < 0.0001; plasma - EPA: +275%, P = 0.0003, DHA: +69%, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 ± 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 ± 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted. Conclusions. Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit.

KW - C-reactive protein

KW - Fish oil

KW - Haemodialysis

KW - n-3

KW - Omega-3

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=36749089036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749089036&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfm422

DO - 10.1093/ndt/gfm422

M3 - Article

C2 - 17623719

AN - SCOPUS:36749089036

VL - 22

SP - 3561

EP - 3567

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 12

ER -